Please login to the form below

Not currently logged in
Email:
Password:

Lucid picks up rare disease and orphan drugs trophy at PMEA 2017

Judges praised the AbbVie project for its impressive reach

Winners

Lucid picked up the award for Excellence in Rare Diseases and Orphan Drugs at this year’s PMEA Awards, which were hosted in London earlier this week.

The agency’s ‘EIDON’ project for AbbVie developed a specialist network and increased the number of specialist centres to advance outcomes of patients with hidradenitis suppurativa (HS).

AbbVie employees, with support from Lucid Group, developed small-group, in clinical training sessions and out of the 62 delegates, 26 of them are establishing new centres, advancing the quality of care in 7,300 patients per year.

PMEA’s judges said: “The Eidon project took a whole programme approach, building awareness from zero to create a network and care delivery infrastructure.

“It is a clearly-structured entry with key behaviours and outcomes defined and measured, and most important, an impressive number of patients were treated.”

Narrowly missing first place, but still achieving a highly commended status on the night was Amicus Therapeutics UK for its work on rare diseases.

Judges said: “Amicus did a very good job for a small outfit in the start-up phase and they showed an extraordinary understanding of payers.”

Run by PMLiVE’s publisher the PMGroup, PMEA exists to reward responsible customer-centric business practices that ensure treatments and advice provide patients with meaningful outcomes.

The programme has been specifically designed to recognise and commend excellence, best practice and innovation in local, European and international markets.

* See all the results from PMEA 2017

* View the PMEA 2017 photo gallery

Article by
Gemma Jones

16th November 2017

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics